Trinity Biotech PLC
IDA Business Park
Bray, Co
Wicklow
Tel: 353-1-276-9800-Or-800-603-8076
Fax: +353-1-276-9888
Website: http://www.trinitybiotech.com/
208 articles about Trinity Biotech PLC
-
Trinity Biotech Plc Finalizes Effective Date of ADS Ratio Change
2/15/2024
Trinity Biotech Plc. announced that it has finalized the effective date of its ratio change of its American depositary shares from one ADS representing four Class A ordinary shares to one ADS representing twenty Class A ordinary shares.
-
Trinity Biotech Plc Announces Plan to Implement ADS Ratio Change
2/13/2024
Trinity Biotech Plc. announced that it plans to change the ratio of the American depositary shares representing its Class A ordinary shares from one ADS representing four Class A ordinary share to one ADS representing twenty Class A ordinary shares.
-
Trinity Biotech to Present at Emerging Growth Conference
2/8/2024
Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), today announces that management will present virtually at the Emerging Growth Conference on March 7, 2024.
-
Trinity Biotech Announces Application for Early Sjogrens Syndrome Test Panel PLA Code
2/7/2024
Trinity Biotech Plc. has applied for a Proprietary Laboratory Analyses (PLA) code for its Early Sjögrens Syndrome Test Panel, to allow for an optimised market access strategy to deliver broader patient access and improved profitability.
-
Trinity Biotech Announces Q3 2023 Financial Results & Business Update-Investor call to be held today at 8:30 am EST
1/31/2024
Trinity Biotech plc (Nasdaq: TRIB) today announced the Company’s results for the quarter ended September 30, 2023.
-
Trinity Biotech Announces Entry into a Letter of Intent with Bayer for a Joint Partnership to Launch a CGM Biosensor Device in China and India
1/31/2024
Trinity Biotech plc announced that it has entered into a non-binding Letter of Intent with Bayer for the launch of a Continuous Glucose Monitoring biosensor device in China and India.
-
Trinity Biotech Announces Acquisition of the CGM Assets of Waveform Technologies, Inc.
1/31/2024
Trinity Biotech plc announced it has entered into a definitive agreement to acquire the biosensor and Continuous Glucose Monitoring assets of privately held Waveform Technologies, Inc. for $12.5 million in cash, 9 million American Depositary Shares of the Company and additional contingent consideration.
-
Trinity Biotech plc to Host Investor Call - Jan 30, 2024
1/30/2024
Trinity Biotech plc, a leading developer and manufacturer of diagnostic solutions for the point-of-care and clinical laboratory markets, will host an investor call on Wednesday, January 31 at 8:30 AM ET to provide an update on business operations.
-
Trinity Biotech Announces It Has Begun Shipments of Its New HIV Screening Test, TrinScreen HIV to Kenya
12/27/2023
Trinity Biotech plc, a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, announces it has begun commercial shipments to Kenya of its new rapid HIV screening test, TrinScreen HIV.
-
Trinity Biotech Announces Management Changes
12/18/2023
Trinity Biotech plc, a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, announced the promotion of John Gillard, our Chief Financial Officer, to President and Chief Executive Officer, effective immediately.
-
Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares
11/28/2023
Trinity Biotech plc announced that on November 21, 2023 the Company received notice from the Nasdaq Stock Market LLC that the Company is not in compliance with the minimum market value of publicly held shares requirement set forth in the Nasdaq Listing Rules.
-
Trinity Biotech Welcomes The Decision Of The High Court Of Kenya To Strike Out The Applications To Prevent the Procurement of TrinScreen HIV By The Kenyan Ministry of Health
10/10/2023
Trinity Biotech plc, a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, welcomes the recent decision by the High Court of Kenya.
-
Trinity Biotech Announces Q2 2023 Financial Results
10/3/2023
Trinity Biotech plc, a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, announced the Company’s results for the quarter ended June 30, 2023.
-
Trinity Biotech plc to Announce Second Quarter Fiscal Year 2023 Financial Results
9/27/2023
Trinity Biotech plc, a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the second quarter fiscal year 2023 on Tuesday, October 3, 2023.
-
Trinity Biotech Announces That It Has Received 510(k) Clearance From The U.S. Food and Drug Administration for the Premier Resolution System
8/7/2023
Trinity Biotech has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Premier Resolution System, an automated analyzer for the accurate & precise quantification of hemoglobins F and A2, and the detection of >200 hemoglobin variants.
-
Trinity Biotech Announces Q1 2023 Financial Results
7/6/2023
Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the Company’s results for the quarter ended March 31, 2023.
-
Trinity Biotech plc to Announce First Quarter Fiscal Year 2023 Financial Results
7/3/2023
Trinity Biotech plc, a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the first quarter fiscal year 2023 on Thursday, July 6, 2023.
-
Trinity Biotech Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
5/5/2023
Trinity Biotech plc reported the receipt of a formal notification from The Nasdaq Stock Market LLC that the Company has regained compliance with Listing Rule 5450, which requires the Company's ordinary shares to maintain a minimum bid price of $1.00 per share.
-
Trinity Biotech Announces the Successful Closing of the $30 Million Sale of its Life Sciences Supply Business to Biosynth
4/27/2023
Trinity Biotech plc announced that it has closed the recently announced sale of its Fitzgerald Industries life sciences supply business, consisting of Benen Trading Ltd and Fitzgerald Industries International, Inc, to Biosynth for cash proceeds of approximately $30 million subject to customary adjustments.
-
Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Minimum Bid Price Requirement
4/24/2023
Trinity Biotech plc announced that on April 19, 2023 the Company received notice from the Nasdaq Stock Market LLC that the Company is not in compliance with Nasdaq Listing Rule 555, as the minimum bid price of the Company’s American depositary shares has been below US $1.00 per share for 30 consecutive business days.